BCAL Diagnostics Limited (BDX) AI Stock Analysis

• Market Cap: AU$21.96M
• Dividend Yield: N/A
• Average Volume (3M): 79.94K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.74
• Revenue Growth: N/A
• EPS Growth: -17.26%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 41
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.01
• Shares Outstanding: 365,967,900
• 10 Day Avg. Volume: 108,285
• 30 Day Avg. Volume: 79,941
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 43 Neutral
• Price Target: AU$0.00 ▼(-100.00% Downside)

The overall stock score of 43 reflects significant challenges in financial performance, driven by ongoing losses and cash flow issues. Technical indicators suggest bearish momentum, and valuation metrics highlight a lack of profitability. The absence of earnings call insights and corporate events data excludes these components from the analysis.

BCAL Diagnostics Limited Business Overview & Revenue Model

Company Description

BCAL Diagnostics Limited, a biotechnology company, engages in developing a non-invasive laboratory blood test for the detection of breast cancer. It develops BCAL test, a lipid biomarker blood test with the potential to be used for breast cancer prevention, screening, and monitoring; and in vitro diagnostic test (IVD) that confirms a fingerprint of lipid biomarkers extracted from extracellular vesicles from a patient's plasma or blood sample to diagnose the presence of breast cancer cells in a patient's body. The company was incorporated in 2010 and is headquartered in Sydney, Australia.

How the Company Makes Money

BCAL Diagnostics Limited generates revenue through the commercialization of its proprietary blood-based diagnostic tests. The company's primary revenue stream comes from selling these diagnostic tests to healthcare providers, clinics, and laboratories. Additionally, BCAL Diagnostics may engage in partnerships or collaborations with other biotech firms and research institutions to further develop and distribute its diagnostic technologies, potentially leading to licensing fees and joint venture earnings. The company may also explore grants or funding from governmental or private institutions to support its research and development efforts.

BCAL Diagnostics Limited Financial Statement Overview

Summary

BCAL Diagnostics Limited is experiencing revenue growth but continues to struggle with profitability and cash flow management. The low leverage provides some financial stability, yet persistent losses and negative cash flows present significant challenges. Strategic improvements are needed to enhance operational efficiency and financial performance.

Income Statement

The company showed a modest revenue growth of 8.59% from 2023 to 2024, but continues to face significant profitability challenges. The gross profit margin remains positive, but both EBIT and EBITDA margins are negative, indicating operational inefficiencies. The net profit margin is also negative, reflecting ongoing losses.

Balance Sheet

The balance sheet shows a relatively stable equity position with a debt-to-equity ratio of 0.18, suggesting low leverage. However, the equity ratio of 70.05% indicates a reliance on equity financing. The return on equity is negative due to net losses, highlighting a lack of profitability.

Cash Flow

Cash flows are under pressure with negative operating and free cash flows. The free cash flow growth rate improved slightly but remains negative. The operating cash flow to net income ratio is not favorable, indicating challenges in converting income into cash.

Breakdown	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	3.10M	2.85M	718.67K	275.25K	442.10K
Gross Profit	3.10M	2.74M	698.06K	275.25K	434.37K
EBITDA	-5.67M	-7.72M	-4.06M	-1.80M	-1.03M
Net Income	-6.40M	-5.06M	-3.39M	-1.52M	-696.36K
Balance Sheet
Total Assets	12.27M	8.37M	10.59M	4.13M	819.55K
Cash, Cash Equivalents and Short-Term Investments	6.47M	3.17M	9.57M	3.41M	416.23K
Total Debt	1.52M	1.06M	0.00	0.00	300.00K
Total Liabilities	3.68M	3.16M	950.42K	525.60K	380.64K
Stockholders Equity	8.59M	5.21M	9.64M	3.61M	438.92K
Cash Flow
Free Cash Flow	-5.67M	-6.41M	-7.25M	-1.21M	-665.46K
Operating Cash Flow	-4.52M	-6.05M	-3.22M	-1.21M	-661.65K
Investing Cash Flow	-1.15M	3.64M	-4.03M	-3.85K	-3.81K
Financing Cash Flow	8.97M	13.24K	9.41M	4.20M	805.04K

BCAL Diagnostics Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.06
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:BDX, the sentiment is Negative. The current price of 0.06 is below the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.06, and below the 200-day MA of 0.09, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 42.48 is Neutral, neither overbought nor oversold. The STOCH value of 25.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:BDX.

BCAL Diagnostics Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	57 Neutral	£5.18B	4.90	-44.55%	2.33%	28.89%	-10.08%
LDX	55 Neutral	AU$78.59M	―	-51.49%	―	80.84%	57.59%
IIQ	49 Neutral	AU$48.56M	―	-39.07%	―	26.07%	0.85%
IBX	47 Neutral	AU$3.94M	―		―	55.07%	88.20%
RHY	45 Neutral	AU$30.54M	―	-71.10%	―	―	76.17%
BDX	43 Neutral	AU$21.96M	―	-104.23%	―	―	-17.26%
WFL	―	$1.48M	―		―	―	―

BCAL Diagnostics Limited Corporate Events

BCAL Diagnostics Expands BREASTEST plus™ Rollout Amid Growing Clinical Recognition

BCAL Diagnostics Limited has launched its BREASTEST plus™ in New South Wales, targeting breast cancer clinics in Sydney and Melbourne. The initial commercial rollout has been successful, with 107 tests sold and partnerships established with eight clinics and 33 breast specialists. The company has expanded its market access strategy to include general practitioners, enhancing doctor engagement and patient referrals. A strategic partnership with Cancer Care Associates has further increased access to the test. The recent policy update by BreastScreen Australia on breast density reporting supports the clinical uptake of BREASTEST plus™, highlighting its importance in early cancer detection where traditional mammography is less effective.

BCAL Diagnostics Partners with Cancer Care Associates to Boost BREASTEST plus™ Adoption

BCAL Diagnostics Limited has announced a strategic partnership with Cancer Care Associates to accelerate the adoption of their non-invasive breast cancer diagnostic test, BREASTEST plus™. This partnership is a significant commercial milestone for BCAL, providing a pathway to market adoption and patient access through a leading oncology network in Australia. The collaboration is expected to generate revenue starting in FY2026 and strengthen BCAL’s commercial rollout strategy, potentially leading to broader national and international partnerships. The integration of BREASTEST plus™ into Cancer Care Associates’ offerings will support uptake in various settings and enhance BCAL’s data collection efforts, aiding discussions around reimbursement and regulatory approvals.

BCAL Diagnostics Expands BREASTEST plus Access in Sydney and Melbourne

BCAL Diagnostics Limited has announced the expansion of its BREASTEST plus blood test to three additional specialist breast clinics in Sydney and Melbourne, starting mid-May 2025. This expansion aligns with BCAL’s national rollout strategy to improve early breast cancer detection in women with high breast density, a group where traditional mammography often faces challenges. The move is a significant milestone in BCAL’s efforts to provide more women with access to this breakthrough diagnostic tool, enhancing early and accurate diagnosis and potentially improving health outcomes.